But because Mounjaro is FDA approved as a diabetes drug, its official prescribing information does not refer to BMI, obesity, or overweight as a qualification for use
Anegawa acknowledges that tapering off of medication is under active study and there isnt research available to show when a person can get off a GLP-1 and successfully maintain weight loss
It is important to have these tests even if you feel well
However, how AMPK regulates GLP-1 signalling pathway needs to be further investigated
The amount of GLP-1 in weight loss injections is so much more than your body produces on its own, so it can help you overcome that resistance while youre on the medication, Messer notes
Several state Medicaid programs now cover GLP-1s for qualifying patients, and proposals have been introduced in Congress to extend Medicare coverage for AOMs.[182] While these proposals carry significant fiscal implications, policy discussions should weigh potential long-term economic benefitsincluding reduced health care costs, improved labor productivity, and positive spillovers in sectors such as infrastructure and transportation, as discussed throughout this report
